BioCentury
ARTICLE | Clinical News

Endotoxin Activity Assay regulatory update

June 23, 2003 7:00 AM UTC

The FDA granted final marketing clearance for SDI's EAA severe sepsis risk test. Earlier this year, FDA said the test qualified for marketing clearance under the de novo process, which is a regulatory...